NASDAQ: VRTX

Vertex Pharmaceuticals (VRTX) Stock Analysis & Forecast

Nov 13 close

$538.60−4.02 (−0.7%)

Gekko Brief

Nov 13 close

Vertex Pharmaceuticals closed at $538.60 on 13 November 2026, -0.7% on the day. The price sits above both the 50-day ($522.37) and 200-day ($483.34) moving averages, inside a 52-week range of $412.27 to $568.67. The GekkoIndex reads 55.1, in the Neutral zone, up 2.1 points over five sessions. Gekko Fair Value is $476.37, so the price is 13.1% above it.

The next earnings report is due on 11 February 2027, 88 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 5.8% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Seasonally, the next 20 trading days from this point averaged +1.1% over the last 5 years, rising in 3 of them.

21 firms rate the stock: 19 buy, 2 hold and 0 sell, with a consensus target of $595.36. A typical daily move is about 3.3%, and a typical 20-day move about 4.4%. On the swing-trade checklist, 4 items read supportive and 1 reads as a headwind (fair value).

A plain summary of the figures as of the Nov 13, 2026 close.

Vertex Pharmaceuticals price vs fair value

$538.60$470.98Nov ’25May ’26Nov ’26
Close $538.60200-day averageGekko Fair Value $470.98

Vertex Pharmaceuticals quick facts

Market cap
$136.6B
P/E ratio
34.9
Forward P/E
26.6
EPS, TTM
$15.54
Revenue, TTM
$12.95B
Profit margin
30.7%
Dividend yield
—
Beta
0.28
Volume
749,454 avg 1.50M
1-year return
+24.0%
Typical daily move
±3.3%
Typical 20-day move
±4.4%
50-day average
$522.37
200-day average
$483.34
Next earnings
Feb 11 after close
Shares outstanding
253.5M
52-week range
$412.27$568.67

Vertex Pharmaceuticals swing-trade checklist

Vertex Pharmaceuticals scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $538.60 is above the 50-day ($522.37) and 200-day ($483.34) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    55.1, Neutral

    Reading 55.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    14.4% above

    Price is 14.4% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +4.0% on average

    From this point in the calendar, the next 20 trading days averaged +4% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Vertex Pharmaceuticals stock chart and price history

Vertex Pharmaceuticals closed at $538.60 on Nov 13, 2026, +24.0% over the past year, inside a 52-week range of $412.27 to $568.67.

Close50-day average200-day averageVolume
Vertex Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$400$450$500$550DecJan 2026FebMarAprMayJunJulAugSepOctNov538.60

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+5.9%
3 months
+4.5%
6 months
+23.3%
1 year
+24.0%
The full VRTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VRTX in Gekko

Follow Vertex Pharmaceuticals through every session

Put VRTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track VRTX in GekkoFree for 7 days. No credit card required.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals makes medicines aimed at cystic fibrosis, a disease tied to mutations in the CFTR gene. Its lineup of cleared drugs, among them SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO and TRIKAFTA, is built around correcting the effects of particular gene defects, and TRIKAFTA is meant for CF patients six years old or older who carry the F508del mutation on at least one allele. This CF-focused portfolio is the foundation the company has built its name on.

Past its established CF business, Vertex runs a wide set of experimental programs at different clinical stages, touching on alpha-1 antitrypsin deficiency, a kidney disorder called APOL1-mediated FSGS, Type 1 diabetes, several categories of pain, and severe sickle cell disease together with transfusion-dependent beta-thalassemia. In the US its drugs move to patients via specialty pharmacies and distribution partners, while sales abroad run through distributors, retail pharmacy chains, hospitals and clinics. The company also pairs with outside research partners, including CRISPR Therapeutics, Moderna, Kymera Therapeutics and Merck KGaA, among others.

Vertex traces back to 1989 and operates out of Boston, Massachusetts. Its stock is listed on the NASDAQ under the ticker VRTX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
vrtx.com

Vertex Pharmaceuticals GekkoIndex: the smart money zone

Vertex Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.1, in the Neutral zone, up 2.1 points over five sessions.

010055.1Neutral

Up 2.1 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying21+1.4%+2.0%+5.7%+13.7%
Accumulation233+0.6%+1.3%+1.7%+5.6%
Neutral (current zone)420+0.1%−0.1%+0.1%−0.4%
Distribution27−0.9%−0.1%+0.6%+3.6%
Selling1Too few readings yet

Average VRTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the VRTX price, zone by zone.Track VRTX in Gekko

Is Vertex Pharmaceuticals stock overvalued? Gekko Fair Value

Vertex Pharmaceuticals trades 14.4% above Gekko Fair Value of $470.98, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Vertex Pharmaceuticals shares are worth, recalculated every trading day.

$470.98

Gekko Fair Value, Nov 14, 2026

14.4% Overvalued

At the end of Aug 2026 the price was 14.3% above the estimate.

Gekko Fair ValueShare price, month end
$471$539Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open VRTX in Gekko

Vertex Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Vertex Pharmaceuticals, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for VRTX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every VRTX insider filing, plotted on the chart in Gekko.Open VRTX in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Oct 9
traded Sep 4

From congressional disclosures, which report amounts as ranges.

Buybacks

Vertex Pharmaceuticals has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$126.7M
As a share of market cap
0.09%
Trailing four quarters
$1.30B

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds VRTX.

0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Vertex Pharmaceuticals earnings: next date and track record

Vertex Pharmaceuticals reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±5.8%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+6.1%Nov ’24−3.0%Feb ’25−10.2%May ’25−18.9%Aug ’25−0.9%Nov ’25+6.6%Feb ’26+0.1%May ’26+0.3%Aug ’26

Last earnings call, Aug 3, 2026 AI summary

What they said
Vertex reported Q2 2026 total revenue growth of 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. Key pipeline milestones include BLA acceptance for Pove in IgAN with a November 30 PDUFA date, expanded CASGEVY labeling for ages 2-11, and cleared IND for VX-017 in Type 1 diabetes. Vertex announced acquisition of Crinetics Pharmaceuticals to establish a fifth pillar in rare endocrine diseases.
Guidance
Vertex expects to complete AMPLITUDE Phase III enrollment by year-end 2026 and report interim analysis results in early 2027. Proof-of-concept study results in DM1 and initial VX-828 patient data expected in second half of 2026. Crinetics acquisition expected to accelerate revenue growth and enhance long-term earnings.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 3, 2026$4.20
est $4.15
+1.2%$3.33B
est $3.23B
+3.2%+0.3%
May 4, 2026$4.47
est $4.31
+3.8%$2.99B
est $2.99B
−0.2%+0.1%
Feb 12, 2026$5.03
est $5.15
−2.3%$3.19B
est $3.18B
+0.2%+6.6%
Nov 3, 2025$4.80
est $4.58
+4.8%$3.08B
est $3.06B
+0.6%−0.9%
Aug 4, 2025$4.52
est $4.29
+5.4%$2.96B
est $2.91B
+2.0%−18.9%
May 5, 2025$4.06
est $4.25
−4.5%$2.77B
est $2.86B
−3.2%−10.2%
Feb 10, 2025$3.98
est $4.02
−1.0%$2.91B
est $2.78B
+4.6%−3.0%
Nov 4, 2024$4.38
est $4.13
+6.1%$2.77B
est $2.69B
+3.2%+6.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Vertex Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Vertex Pharmaceuticals is $595.36, +10.5% from the last close, from 21 firms rating the stock in the last 90 days.

$595.36consensus 12-month target, +10.5% from the last close
Low $442High $725
Buy19
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 21 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12Bank of America SecuritiesBuy, maintained——
Nov 4H.C. WainwrightBuy, reiterated$641+19.0%
Nov 4BarclaysBuy, maintained$626+16.2%
Nov 4UBSBuy, maintained$640+18.8%
Nov 3H.C. WainwrightBuy, maintained$641+19.0%
+0.1%average 20-day move after past Neutral readings
+4.0%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Vertex Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Vertex Pharmaceuticals averaged +4.0% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

+12.0%2021+0.3%2022+9.5%2023−4.2%2024+4.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.0%1 of 5
Next 10 trading days−2.1%2 of 5
Next 15 trading days+0.3%3 of 5
Next 20 trading days+4.0%4 of 5
Next 30 trading days+2.0%3 of 5

For scale, VRTX’s typical 20-trading-day move in either direction is about 4.4%.

Vertex Pharmaceuticals market cap and key statistics

Vertex Pharmaceuticals’s market cap is $136.6B, with a P/E ratio of 34.9 and revenue of $12.95B over the last twelve months.

Valuation

Market cap
$136.6B
P/E ratio
34.9
Forward P/E
26.6
EPS, TTM
$15.54
Gekko Fair Value
$470.98

Trading

Volume
749,454
Avg volume, 20 days
1.50M
52-week high
$568.67
52-week low
$412.27
Shares outstanding
253.5M

Financials

Revenue, TTM
$12.95B
Profit margin
30.7%
Return on equity
20.8%
Quarterly earnings growth, YoY
−39.0%

Risk and income

Beta
0.28
Typical daily move
±3.3%
Typical 20-day move
±4.4%

Vertex Pharmaceuticals stock news this week

Coverage of Vertex Pharmaceuticals this week reads positive: 8 positive, 6 neutral and 0 negative headlines.

News sentiment positive

Vertex Pharmaceuticals peers

Vertex Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Vertex Pharmaceuticals stock FAQ

What is Vertex Pharmaceuticals’s market cap?

Vertex Pharmaceuticals’s market cap is $136.6B at the Nov 13, 2026 close of $538.60, with 253.5M shares outstanding. The shares trade on a P/E ratio of 34.9.

What is the Vertex Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Vertex Pharmaceuticals is $595.36, +10.5% from the last close. Of the 21 firms that rated the stock in the last 90 days, 19 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Vertex Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Vertex Pharmaceuticals is overvalued: the Nov 13, 2026 close of $538.60 is 14.4% above Gekko Fair Value of $470.98. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Vertex Pharmaceuticals report earnings next?

Vertex Pharmaceuticals is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of $4.20 per share on revenue of $3.50B. Vertex Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 5.8% on average across the report.

What is Vertex Pharmaceuticals’s 52-week high and low?

Vertex Pharmaceuticals’s 52-week high is $568.67 and its 52-week low is $412.27; it closed at $538.60 on Nov 13, 2026, +24.0% over the past year.

Is Vertex Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Vertex Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.